Details of the Drug Combination

General Information of Drug Combination (ID: DCQ1U2D)

• Drug Combination Name: Cabazitaxel + BIO-300
• Indication: Carcinoma; Status: Investigative [1]
• Component Drugs:
  Cabazitaxel (DMPAZHC): Small molecular drug
  BIO-300 (DMJ7NVI): N.A.
• High-throughput Screening Result:
  Testing Cell Line: RXF 393
  Zero Interaction Potency (ZIP) Score: 7.92
  Bliss Independence Score: 8.03
  Loewe Additivity Score: 14.66
  LHighest Single Agent (HSA) Score: 16.83

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Cabazitaxel

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Metastatic prostate carcinoma	N.A.	Investigative	[3]

Cabazitaxel Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[6]

Cabazitaxel Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[7]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[7]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[7]

Cabazitaxel Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Forkhead box protein O3 (FOXO3)	OTHXQG4P	FOXO3_HUMAN	Affects Expression	[8]
Proline-rich AKT1 substrate 1 (AKT1S1)	OT4JHN4Y	AKTS1_HUMAN	Decreases Expression	[8]

Indication(s) of BIO-300

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
Rheumatoid arthritis	FA20	Phase 1	[5]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCDNN52	A549	Investigative	[9]
Adenocarcinoma	DCQV82G	HT29	Investigative	[9]
Adenocarcinoma	DC1HKCV	HCT-15	Investigative	[9]
Adenocarcinoma	DCHIS3E	HCT116	Investigative	[9]
Adult acute myeloid leukemia	DCQLZ5V	HL-60(TB)	Investigative	[9]
Adult T acute lymphoblastic leukemia	DCLA0DV	MOLT-4	Investigative	[9]
Anaplastic large cell lymphoma	DCU2NWH	SR	Investigative	[9]
Astrocytoma	DCMA8A0	SNB-19	Investigative	[9]
Childhood T acute lymphoblastic leukemia	DCDJYHB	CCRF-CEM	Investigative	[9]
Clear cell renal cell carcinoma	DCDJX8Y	786-0	Investigative	[9]
Clear cell renal cell carcinoma	DC9ASEF	A498	Investigative	[9]
Cutaneous melanoma	DC9OHKE	SK-MEL-28	Investigative	[9]
Glioblastoma	DC2CJHQ	SNB-75	Investigative	[9]
Glioma	DCDJL2T	SF-295	Investigative	[9]
High grade ovarian serous adenocarcinoma	DCON9OV	OVCAR-8	Investigative	[9]
Large cell lung carcinoma	DC2QQQV	NCI-H460	Investigative	[9]
Lung adenocarcinoma	DC5913L	HOP-62	Investigative	[9]
Prostate carcinoma	DCPGGX9	PC-3	Investigative	[9]
Renal cell carcinoma	DCX9UIH	SN12C	Investigative	[9]
Renal cell carcinoma	DCE5X1J	UO-31	Investigative	[9]
Breast adenocarcinoma	DCOOHUB	MDA-MB-468	Investigative	[1]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
• [3] Cabazitaxel FDA Label
• [4] Clinical pipeline report, company report or official report of Humanetics.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [7] DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
• [8] The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol. 2020 Aug 15;401:115091. doi: 10.1016/j.taap.2020.115091. Epub 2020 Jun 7.
• [9] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966